The method of treatment of purulent wounds in the experiment

 

The invention relates to medicine, and is intended for the treatment of purulent wounds in the experiment. Put ferromagnetic ointment on the wound surface. Then the pre-formed shape of the wound tape with steel rods and a source of constant magnetic field bring to the wound for 1-3 minutes Method can improve the effectiveness of treatment of purulent wounds in the experiment. 1 Il.

The invention relates to medicine, namely to the use of magnetic fields in surgery, and can be used for the treatment of purulent wounds, trophic ulcers and so on

Struggle with purulent surgical infection remains one of the urgent problems of modern medicine. The growth of complicated forms of wound infection and the steady growth of antibiotic-resistant microflora makes the search for new methods of treatment, which would quickly clean the wound, increase local immunity, thereby to accelerate the regenerative processes in the wound. One of such ways is magnetotherapy, more precisely the use of ferromagnets. Even in the absence of an external magnetic field ferromagnets are in the saturation state (spontaneous magnetization). The basis of ferromagnetism - ferromagnetic registration fields; 2) transformer magnetic energy into mechanical energy and heat; 3) a source of magnetic energy; 4) the magnetic field modifier.

As a result of numerous medical and biological experiments revealed that biological environment - lymph, blood, destroys part of the polymer filler, without touching FMC. In the surface layer of microcrystal acquires a large number of pores, thus providing an ability to absorb them in molecule toxins, microorganisms, and dead cells. On this property with other properties based methods of treatment of purulent wounds with the use of ferromagnetic ointments.

As the prototype is set to the known method of treatment of purulent wounds, including the application of ferromagnetic ointment on the wound surface, the magnetic field created by the ointment, and debridement using an external DC magnetic field (see Cybusov S. N. the article "the Use of magnetic ointments for the treatment of purulent wounds in the experiment in sa-ke "Influence of electromagnetic fields on the human body" Ed. by D. F. N. O. G. Cherkasova, M., Foundation for the New Millennium", 1998, pp. 156-158).

The known method is as follows: established in experimental conditions min. The wound covered with a cloth and apply a permanent magnet at a distance of 0.5 cm from napkins for 5 minutes. FMM with exhaust products magnets to the external DC magnetic field. The contents of the wounds were evacuated.

There is a method allows: 1) after a single application of FMM infection of the wound is reduced 1000 times and healing is 1.5 times faster than in animals of the control group; 2) to reduce the inflammatory process; 3) to accelerate the growth of granulation tissue; 4) to encourage the restoration of regional blood flow.

However, the disadvantage of this method is the difficulty in cleaning wounds from a waste product. As you know, the wounds are different in configuration, size, depth, etc., and may not always be possible to completely clean, that is, to remove FMM products pus, collapse at once.

The task of the invention is to increase the effectiveness of treatment of purulent wounds by accelerating and improving the quality of cleaning wounds.

This object is achieved in that in the known method of treatment of purulent wounds in the experiment, including the application of ferromagnetic ointment on the wound surface, the magnetic field, with the d's small foci maximum inhomogeneous magnetic field exposure for 1-3 minutes.

The drawing shows the proposed method of treatment of purulent wounds and device for its implementation.

The drawing shows: 1 - purulent wound
2 - cassette with magnetic
3 - permanent magnet
The proposed method is as follows.

Under the General ether anesthesia in outbred rats at the site back cause cutaneous wound up muscle size 22 see the wound dropper put a 0.2 ml suspension of staphylococci daily culture, diluted to 104. Samples from the surface of infected wounds were taken according to the method of N. B. Mordvinova. After the wound is inflicted 0.1 ml of ferromagnetic materials. Magnetic ointment is a mixture of ointment bases (lanolin-petrolatum) and fine magnetite with the size of the microcrystals from 100 to 300 And with a stabilizer. At body temperature the ointment is a viscous, hydrophobic and high adhesive. Magnetization ointment ranges from 40 to 60 A/m Ointment connects easily with purulent content. Exposure of the magnetic ointment on the wound for 5-7 minutes. Wound 1 (drawing) covered with a napkin and bring the cartridge 2 with steel rods and an external DC magnetic field 3, the pre-formed shape of the wound, thereby creating in the wound the maximum is "novelty", as held patent information research did not reveal sources prejudicial to the novelty of the invention.

The present invention meets the criterion of "inventive step", because in the process of searching revealed no analogues having the essential features of the proposed method.

The proposed method allows to obtain the following positive effects.

Get a high inhomogeneity of the magnetic field allows to Orient the ferromagnetic particle with enveloping her purulent contents to the nearest source of magnetic field, improves the evacuation of the magnetic particles, thereby providing the ability to facilitate cleaning of the wound. Bacteriostatic effect is provided due to the high inhomogeneity of the magnetic field. In addition, an additional therapeutic effect of acceleration of wound healing due to the ordered set of sources most of the concentrated magnetic field. Exposure time of 3 min is sufficient for cleansing and therapeutic effects.

Example 1. Laboratory animal 27. The treatment proposed method purulent wound size 22 cm the resulting reduction of terms of epithelialization of wounds on 4 days on Sri wounds proposed method achieved a faster epithelialization of the wound compared with the control group at 5 days.


Claims

The method of treatment of purulent wounds in the experiment, including the application of ferromagnetic ointment on the wound surface, the magnetic field influence on the wound created by the external DC magnetic field and its treatment, wherein the pre-formed shape of the wound tape with steel rods and a source of constant magnetic field bring to the wound for 1-3 minutes

 

Same patents:
The invention relates to medicine, gastroenterology, Oncology
The invention relates to medicine and can be used to treat endourethral warts, localized in the posterior third of the hanging part of the urethra

The invention relates to medicine

The invention relates to the field of health and can be used for non-contact massage body tissues, prevention and treatment of diseases of the joints, skeletal system, muscles, blood vessels, etc
The invention relates to medicine, and is intended for the treatment of psoriatic arthritis

The invention relates to medicine, and is intended for the treatment of chronic adnexitis

The invention relates to medical equipment, namely, magnetic therapy, and is intended for the treatment of many diseases, including gastrointestinal - liver cirrhosis with portal hypertension and splenomegaly, chronic hepatitis, cholecystitis and cholelithiasis, pancreatitis, peptic ulcer and 12 duodenal ulcer; urological diseases, pyelonephritis, urolithiasis, the implementation of regeneration nonfunctioning kidneys, etc

The invention relates to medical equipment, namely, magnetic therapy, and can be used in the treatment of many diseases, including cirrhosis of the liver complicated forms in the course of regeneration of dysfunctional organs, the treatment of BPH, provides painless crushing and output concretions of various organs, treats mastitis and fibroadenoma of the mammary glands and uterine fibroids, atherosclerosis of vessels of lower extremities and many others without surgery and without the use of medication

The invention relates to medical equipment and can be used for magnetic therapy, and to examine the effect of variable low frequency of vortex magnetic fields on biological objects

The invention relates to medicine and intended for the introduction of ions of metallic silver

FIELD: medicine.

SUBSTANCE: method involves making incision in conjunctiva and Tenon's capsule of 3-4 mm in size in choroid hemangioma projection to sclera 3-4 mm far from limb. Tunnel is built between sclera and Tenon's capsule to extrasclerally introduce flexible polymer magnetolaser implant through the tunnel to the place, the choroid hemangioma is localized, after performing transscleral diaphanoscopic adjustment of choroid hemangioma localization and size, under visual control using guidance beam. The implant has permanent ring-shaped magnet in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 2-3 mTesla units intensity. It is arranged with its north pole turned towards the choroid hemangioma so that extrascleral implant laser radiator disposition. The other end of the implant is sutured to sclera 5-6 mm far from the limb with two interrupted sutures through prefabricated openings. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. 0.1-1% khlorin solution is injected in intravenous bolus dose of 0.8-1.1 mg/kg as photosensitizer and visual control of choroid hemangioma cells fluorescence and fluorescent diagnosis methods are applied. After saturating choroid hemangioma with the photosensitizer to maximum level, transscleral choroid hemangioma laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm with total radiation dose being equal to 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the intraocular neoplasm, repeated laser irradiation of the choroid hemangioma is carried out with radiation dose of 30-60 J/cm2.

EFFECT: enhanced effectiveness of treatment.

4 cl

FIELD: medicine.

SUBSTANCE: method involves creating tunnel between sclera and Tenon's capsule in intraocular neoplasm projection. Intraocular neoplasm localization and size is adjusted by applying transscleral diaphanoscopic examination method. 0.1-0.3 ml of photosensitizing gel based on viscoelastic of hyaluronic acid, selected from group containing chealon, viscoate or hyatulon, is transsclerally introduced into intraocular neoplasm structure using special purpose needle in dosed manner. The photosensitizing gel contains khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-1% by mass. Flexible polymer magnetolaser implant is extrasclerally introduced into the built tunnel in intraocular neoplasm projection zone under visual control using guidance beam. The implant has permanent ring-shaped magnet axially magnetized and producing permanent magnetic field of 3-4 mTesla units intensity, in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The implant is arranged with its north pole turned towards the intraocular neoplasm so that implant laser radiator lens is extrasclerally arranged in intraocular neoplasm projection zone. The implant light guide is sutured to sclera 5-6 mm far from the limb with single interrupted suture. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transscleral intraocular neoplasm laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm. The treatment course being over, the flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, neodymium-iron-boron or samarium-iron-nitrogen. 0.1-1% khlorin solution as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is additionally intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg and repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2 15-20 min later during 30-90 s.

EFFECT: complete destruction of neoplasm; excluded its further growth.

4 cl

FIELD: medicine.

SUBSTANCE: method involves building tunnel to posterior eyeball pole in inferoexterior and superexterior quadrants. The tunnel is used for implanting flexible polymer magnetolaser implant to the place, the subretinal neovascular membrane is localized. The implant has a permanent magnet shaped as a cut ring and is provided with drug delivery system and a short focus scattering lens of laser radiator connected to light guide. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 5-7 mTesla units intensity. It is arranged with its north pole turned towards sclera at the place of the subretinal neovascular membrane projection with extrascleral arrangement of laser radiator lens membrane being provided in the subretinal neovascular membrane projection area. The other implant end is sutured to sclera 5-6 mm far from the limb via holes made in advance. The implant is covered with conjunctiva and retention sutures are placed thereon. Light guide and drug supply system lead is attached to temple with any known method applied. Drugs are supplied via the implant drug supply system in retrobulbary way in any order. Triombrast is given in the amount of 0,4-0,6 ml and dexamethasone or dexone in the amount of 0,4-0,6 ml during 3-4 days every 12 h. 0.1-1% aqueous solution of khlorin is intravenously introduced at the third-fourth day after setting the implant as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, at a bolus dose of 0.8-1.1 mg/kg. Visual control of subretinal neovascular membrane cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the subretinal neovascular membrane with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at general dose of 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the subretinal neovascular membrane via laser light guide and implant lens, repeated laser irradiation of the subretinal neovascular membrane is carried out with radiation dose of 30-60 J/cm2.

EFFECT: accelerated subretinal edema and hemorrhages resorption; regression and obliteration of the subretinal neovascular membrane; prolonged vision function stabilization.

6 cl

FIELD: medicine.

SUBSTANCE: method involves carrying out transpupillary laser avascular zones coagulation. Taurin is dropped into conjunctival cavity at a dose of 1-2 drops into the eye under treatment 5-6 times a day during 7-10 days. 0.02% Histochrome solution is dropped into conjunctival cavity at a dose of 2 drops into the eye under treatment 5-6 times a day during 7-10 days. 0.02% Histochrome solution or 0.02% Emoxipin solution or 1% Retinalamine solution in the amount of 0.4-0.6 ml once a day is parabulbary introduced as antioxidant during 7-10 days. Magnetic stimulation course is applied on the background of conservative therapy to orbital or temporal head region of prematurely born child in any succession using external rotating permanent magnetic field of 0.15-0.40 mTesla units intensity. Periodicity of external magnetic field action is selected to be 1-2 times per day with external action duration being equal to 3-5 min per 1 session during 10 days with magnetic field being 15-30 cm far from orbital or temporal head region of prematurely born child. External permanent magnetic field rotating at constant or variable speed is applied for carrying out magnetic stimulation treatment. Repeated conservative therapy and magnetic stimulation treatment with external rotating permanent magnetic field is additionally applied in 1-3 months. The number of repeated courses is equal to 1-3.

EFFECT: enhanced effectiveness of prophylactic treatment; prevented severe disease forms progress; released retina edema; improved blood circulation in avascular zones.

3 cl

FIELD: medicine.

SUBSTANCE: method involves carrying out transpupillary laser coagulation of central avascular zones and transscleral cryocoagulation of peripheral avascular retina zones. 3-4 mm long incisions in conjunctiva and Tenon's capsule are done between sclera and Tenon's capsule in perpendicular to limbus 3-4 mm far from it. Tunnel is built in projection zone of an avascular retina zone between sclera and Tenon's capsule in parallel to the limbus on both sides of the incision. Flexible polymer magnetic implant is extrasclerally introduced into the tunnel in projection zone of an avascular retina zone. The implant has its own permanent magnetic field with magnetic poles alternating on each of sides and permanent magnetic field intensity of 0.5-1.0 mTesla units. The implant is sutured with one of its ends to sclera, and suture is placed on conjunctiva, and anti-oxidant therapy is applied. Magnetic stimulation therapy course is applied 3-4 weeks later. The course combines actions of permanent magnetic field produced by extrasclerally arranged magnetic implant and external rotating permanent magnetic field of 0.30-0.40 mTesla units intensity. Periodicity of external magnetic field action is selected to be 1-2 times per day with external action duration being equal to 3-5 min per 1 session during 10 days. The extrasclerally arranged flexible polymer magnetic implant is removed when treatment course is over. The flexible polymer magnetic implant is manufactured from biologically stable polymer material like one on polypropylene, polyester or polyethylene basis having permanent magnet material powder particles uniformly distributed therein. Magnetic material particles are of samarium-cobalt, neodymium-iron-boron or samarium-iron-nitrogen base.

EFFECT: enhanced effectiveness of prophylactic treatment; prevented severe disease forms progress; released retina edema.

6 cl

FIELD: medicine.

SUBSTANCE: method involves carrying out vitrectomy with posterior hyaline membrane being removed. Retinotomy is carried out with subretinal neovascular complex being removed. Autogenous pigment retinal epithelium is subretinally introduced through retinotomy area as stratum or suspension. The intravitreous tamponade is carried out with perfluororganic compound substituted with air next to it. Flexible polymer magnetolaser implant having ring-shaped magnet with axial permanent magnetic field magnetization of 3-7 mTesla units is extrasclerally mounted into tunnel built between sclera and Tenon's capsule in macular area projection zone. The implant is turned with S pole towards transplanted cells so that laser radiation-emitting lens is arranged in their projection zone. Implant light guide is sutured to sclera 5-6 mm far from limb. The implant is covered with conjunctiva. Light guide outlet is attached to temple. The introduced cells are treated via laser light guide and implant lens with divergent continuous laser radiation. The magnetic implant is removed after having finished the treatment course and sutures are placed on conjunctiva.

EFFECT: enhanced effectiveness of treatment.

FIELD: medical engineering.

SUBSTANCE: method involves acting in turn with ultrasonic and magnetic field with switch frequency of 10 to 160 Hz. Ultrasonic field intensity is set below cavitation threshold and ultrasonic oscillation frequency being equal to liquid acoustic relaxation frequency. Magnetic field induction being selected within the limits of 30-50 mTesla units.

EFFECT: enhanced effectiveness of liquid activation; reduced power consumption.

1 dwg

FIELD: medicine, surgery.

SUBSTANCE: the present innovation deals with operative interference followed by the impact with magnetolaser infrared radiation of 80 Hz frequency per 30 sec or 2-4 fields and with direct magnetic field at the value of magnetic induction being 25-50 mTl for 10-20 min successively. At first, one should affect postoperational area, the - reflexogenic area at one's foot, daily for 8-12 d. Since the 9th - 13th d one should affect with single direct magnetic field with the value of magnetic induction being 25-50 mTl for 10-20 min successively. At first, one should affect postoperational area, then - reflexogenic area at one's foot for 10 -12 d. The innovation decreases the frequency of postoperational complications.

EFFECT: shortened terms of therapy.

2 ex

Medical applicator // 2269368

FIELD: medical engineering.

SUBSTANCE: device has metal casing having permanent magnet inside. Electrode is outside of the casing and connected to electric current source. The second electrode, manufactured from non-magnetic material having cavity, is inside of the casing. Permanent magnetic is mounted in the cavity. Substance like mineral solution or plant oil is placed between the electrodes. Dielectric bushing is mounted in the casing for insulating electrodes and substance from the casing. Electric current supply source is mounted with one of its contacts on the first electrode and with its second electrode having ironwork fault. One of applicator embodiments has spring placed between electric current supply source and casing. Another version has electrode mounted outside of the casing. It is manufactured from nonferrous metal having silver coating.

EFFECT: wide range of functional applications.

3 cl, 1 dwg

FIELD: medicine.

SUBSTANCE: method involves rectally exposing prostate projection zone to red, infrared radiation, magnetic field and magnetic therapy is applied to sacral region, pubis and perineum. Magnetized sapropelic tampon is introduced into the rectum after applying combined rectal treatment. Tampon volume is equal to 140-160 ml and hold for 30-40 min under temperature of 37-38°C and magnetic therapy is applied to sacral region, pubis and perineum region.

EFFECT: wide range of therapeutic applications.

Up!